{"uid":"cap_htp5i1X3rpKxcfD2EeAtp","slug":"clinicalintelpulse-pipeline-scan-88bf5074","name":"ClinicalIntelPulse Pipeline Scan","description":"Clinical trial pipeline scan for any disease — all active Phase 2/3 trials with trial counts, sponsor landscape, geographic distribution, mechanism breakdown and pipeline density, across 400,000+ trials worldwide. For biotech-investing and pharma agents.","url":"https://clinicalintelpulse.vercel.app/api/clinical/pipeline-scan","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"phase":{"type":"string"},"status":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"query_summary":{"condition":"Non-Small Cell Lung Cancer","status_filter":"RECRUITING,ACTIVE_NOT_RECRUITING","phases_searched":["PHASE2","PHASE3"]},"pipeline_totals":{"phase2_count":156,"phase3_count":89,"total_active":245},"phase3_highlights":[{"nctId":"NCT05116748","title":"Pembrolizumab + Carboplatin vs SOC in NSCLC","status":"RECRUITING","sponsor":"Merck","countries":["United States","Germany","Japan","South Korea"],"primaryCompletion":"2026-03"}],"sponsor_landscape":{"academic_sponsors":"ECOG-ACRIN, Alliance, NCI leading academic cooperative groups","emerging_biotechs":["Turning Point Therapeutics","Blueprint Medicines","Mirati Therapeutics"],"top_industry_sponsors":["Roche/Genentech (18 trials)","Bristol-Myers Squibb (14)","AstraZeneca (13)","Merck (12)","Pfizer (11)"]},"mechanism_breakdown":{"adc":18,"other":81,"bispecific":12,"targeted_therapy":41,"chemo_combinations":31,"io_checkpoint_inhibitors":62},"pipeline_assessment":"Extremely crowded pipeline — PD-1/L1 space saturated. ADCs and bispecifics represent highest differentiation potential. KRAS G12C targeted therapies emerging as new standard.","approved_drugs_context":"NSCLC has 30+ FDA-approved agents. Pipeline is additive rather than disruptive in most cases.","geographic_distribution":{"asia_pct":22,"other_pct":5,"europe_pct":28,"us_trials_pct":45,"most_active_countries":["United States","China","Germany","South Korea","Japan"]}}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.15","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.15/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.15","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.15","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_VmHzytv8FS7IzwBmUBkFn","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.15","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns a broad-sweep analysis of all active Phase 2/3 clinical trials for any disease worldwide, including trial count, sponsor landscape, geographic distribution, and pipeline density across 400,000+ trials.","exampleAgentPrompt":"Give me a full pipeline scan for non-alcoholic steatohepatitis — I want to know how many active Phase 2 and Phase 3 trials exist worldwide, who the major sponsors are, and how geographically distributed the activity is.","exampleUseCases":[{"title":"Competitive landscape assessment for rare disease","prompt":"I'm evaluating whether to enter the Duchenne muscular dystrophy space as a new biotech. Can you scan the entire Phase 2 and Phase 3 pipeline for DMD worldwide? I need to know how many trials are active, which companies and academic centers are leading the charge, and where the trial sites are concentrated geographically."},{"title":"Pipeline crowding analysis for fund strategy","prompt":"Our venture fund is sizing opportunities in neurodegenerative diseases. Give us a broad overview of the clinical trial landscape for amyotrophic lateral sclerosis — how many Phase 2 and Phase 3 trials are currently running, who are the major sponsors, and what does the geographic distribution tell us about regional focus?"},{"title":"Market maturity check for indication planning","prompt":"We're considering IPO timing for our immunology platform and need to benchmark our pipeline strength. Can you pull a full scan of the systemic lupus erythematosus clinical landscape? I want the total active Phase 2 and Phase 3 trial count, sponsor breakdown between biotech, pharma, and academic players, and how trials are distributed across major regions."}],"resultDescription":"Returns structured data including total count of active Phase 2/3 trials for the queried disease, a breakdown of sponsor organizations (biotech, big pharma, academic), geographic distribution of trial sites across regions, and a pipeline density score or summary — all drawn from a database of 400,000+ trials.","failureModes":["Unknown or misspelled disease name returns empty result or error","Very rare diseases may return very low trial counts or no data","Service unavailable returns HTTP 402 or 5xx if payment fails","Ambiguous disease names (e.g. 'cancer') may require more specificity","Rate limiting or quota exceeded if called too frequently"],"whenToPreferThis":"Use this endpoint when you need a broad, market-level view of the clinical pipeline for a specific disease — ideal for biotech investors assessing competitive crowding, pharma strategists sizing an indication, or analysts benchmarking pipeline activity. Prefer this over deeper single-trial or company-specific endpoints when the goal is landscape-level intelligence rather than granular trial design details.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-15T12:51:50.764Z","isFirstParty":false}